Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study.
Ayse Irem YasinSabin Göktas AydinBilge SümbülLokman KoralMelih SimsekÇağlayan GeredeliAkın ÖztürkPerihan PerkinDerya DemirtaşEngin Erdemogluİlhan HacıbekirogluEmre ÇakırEda TanrıkuluEzgi ÇobanMelike OzcelikSinemis ÇelikFatih TekerAsude AksoySedat T FıratÖmer TekinZiya KalkanOrhan TürkenBala B OvenFaysal DaneAhmet BiliciAbdurrahman IsıkdoganMesut SekerHacı M TürkMahmut GümüşPublished in: Future oncology (London, England) (2022)
Aim: To compare the seropositivity rate of cancer patients with noncancer controls after inactive SARS-CoV-2 vaccination and evaluate the factors affecting seropositivity. Method: Spike IgG antibodies against SARS-CoV-2 were measured in blood samples of 776 cancer patients and 715 noncancer volunteers. An IgG level ≥50 AU/ml is accepted as seropositive. Results: The seropositivity rate was 85.2% in the patient group and 97.5% in the control group. The seropositivity rate and antibody levels were significantly lower in the patient group (p < 0.001). Age and chemotherapy were associated with lower seropositivity in cancer patients (p < 0.001). Conclusion: This study highlighted the efficacy and safety of the inactivated vaccine in cancer patients. Clinical Trials Registration: NCT04771559 (ClinicalTrials.gov).